Medicine Lodge Creek?
But if the government created a $100 million research pool for childhood cancers and ensured a collaborative approach, it could address a variety of diseases and the consequences of common treatments, she said.
Australia's treatment protocol for neuroblastoma has only undergone one change in the last decade, Neuroblastoma Australia CEO Lucy Jones says, which means patients haven't been able to substitute the more toxic drugs with newer and safer alternatives.
Red tape can also block access to life-saving medicines, which must undergo clinical trials in Australia, even if they are found to be effective in the US and Europe, and the entire approval process takes 18 months on average.
It has also offered grants for children's brain cancer research, committing $20 million for polkadot chocolate research into Diffuse Intrinsic Pontine Glioma (DIPG) in February, and $15 million into drug development research for prostate and childhood cancers like neuroblastoma.
In the US and Europe however, drug companies receive government funding to research childhood cancer, giving those regions greater access to innovative and world-leading solutions that leave less significant after-effects.
Australia's treatment protocol for neuroblastoma has only undergone one change in the last decade, Neuroblastoma Australia CEO Lucy Jones says, which means patients haven't been able to substitute the more toxic drugs with newer and safer alternatives.
Red tape can also block access to life-saving medicines, which must undergo clinical trials in Australia, even if they are found to be effective in the US and Europe, and the entire approval process takes 18 months on average.
It has also offered grants for children's brain cancer research, committing $20 million for polkadot chocolate research into Diffuse Intrinsic Pontine Glioma (DIPG) in February, and $15 million into drug development research for prostate and childhood cancers like neuroblastoma.
In the US and Europe however, drug companies receive government funding to research childhood cancer, giving those regions greater access to innovative and world-leading solutions that leave less significant after-effects.